{"title":"Emergence of a New Sublineage of <i>Candida auris</i> Causing Nosocomial Transmissions - Beijing Municipality, China, March-September 2023.","authors":"Zhenjia Liu, Xinfei Chen, Rongchen Dai, Yu Bai, Feiyi Liu, Yiying Zhao, Xuesong Shang, Chunxia Yang, Xin Fan","doi":"10.46234/ccdcw2024.233","DOIUrl":null,"url":null,"abstract":"<p><strong>What is already known about this topic?: </strong><i>Candida auris</i> (<i>C. auris</i>) is an emerging multidrug-resistant fungal pathogen classified as a global public health threat with notable mortality and nosocomial transmission capacity. In China, the first <i>C. auris</i> case was reported from Beijing in 2018. However, large cases of nosocomial transmission have rarely been identified in this municipality.</p><p><strong>What is added by this report?: </strong>During March-September 2023, <i>C. auris</i> was isolated from 17 patients admitted to CY Hospital in Beijing. All strains were resistant to fluconazole and amphotericin B. In addition, three isolates were resistant to echinocandins. Whole-genome sequencing (WGS) analysis revealed that all strains found in this hospital belonged to <i>C. auris</i> Clade I. These strains were genetically closely related to the <i>C. auris</i> strains reported in two other hospitals in Beijing since 2021, forming a new sublineage different from the Clade I strains causing previous outbreaks in the Eastern Provincial-level administrative divisions and Hong Kong Special Administrative Region.</p><p><strong>What are the implications for public health practice?: </strong>The dissemination of <i>C. auris</i> has become an increasing threat to healthcare facilities in China. The WGS analysis indicates the spread of a unique sublineage of <i>C. auris</i> Clade I isolates in Beijing. Further, enhanced surveillance and hospital infection control of <i>C. auris</i> are warranted to resolve the public health challenge.</p>","PeriodicalId":69039,"journal":{"name":"中国疾病预防控制中心周报","volume":"6 44","pages":"1147-1151"},"PeriodicalIF":4.3000,"publicationDate":"2024-11-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11561371/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"中国疾病预防控制中心周报","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.46234/ccdcw2024.233","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"PUBLIC, ENVIRONMENTAL & OCCUPATIONAL HEALTH","Score":null,"Total":0}
引用次数: 0
Abstract
What is already known about this topic?: Candida auris (C. auris) is an emerging multidrug-resistant fungal pathogen classified as a global public health threat with notable mortality and nosocomial transmission capacity. In China, the first C. auris case was reported from Beijing in 2018. However, large cases of nosocomial transmission have rarely been identified in this municipality.
What is added by this report?: During March-September 2023, C. auris was isolated from 17 patients admitted to CY Hospital in Beijing. All strains were resistant to fluconazole and amphotericin B. In addition, three isolates were resistant to echinocandins. Whole-genome sequencing (WGS) analysis revealed that all strains found in this hospital belonged to C. auris Clade I. These strains were genetically closely related to the C. auris strains reported in two other hospitals in Beijing since 2021, forming a new sublineage different from the Clade I strains causing previous outbreaks in the Eastern Provincial-level administrative divisions and Hong Kong Special Administrative Region.
What are the implications for public health practice?: The dissemination of C. auris has become an increasing threat to healthcare facilities in China. The WGS analysis indicates the spread of a unique sublineage of C. auris Clade I isolates in Beijing. Further, enhanced surveillance and hospital infection control of C. auris are warranted to resolve the public health challenge.
关于本专题的已知情况:白色念珠菌(C. auris)是一种新出现的多重耐药真菌病原体,被列为全球公共卫生威胁,具有显著的致死率和病原菌传播能力。在中国,2018年北京报告了首例C. auris病例。然而,该市很少发现大规模的院内传播病例:2023年3月至9月期间,从北京CY医院收治的17名患者中分离出了阿氏杆菌。所有菌株均对氟康唑和两性霉素 B 耐药。全基因组测序(WGS)分析表明,该医院发现的所有菌株均属于中华鹅口疮Ⅰ支系。这些菌株与2021年以来北京另外两家医院报告的中华鹅口疮菌株在基因上密切相关,形成了一个新的亚系,不同于此前在东部省级行政区和香港特别行政区暴发的中华鹅口疮Ⅰ支系菌株:法氏囊病菌的传播对中国医疗机构的威胁日益严重。WGS 分析表明,在北京,C. auris 支系 I 分离物的一个独特亚系正在传播。此外,要解决这一公共卫生挑战,必须加强对 C. auris 的监测和医院感染控制。